SCM
AMLX icon

Stonepine Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Stonepine Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,500,000
Closed -$36.8M – 21
2023
Q4 		$36.8M Sell
2,500,000
-15,868
-0.6% -$243K 15.92% 3
2023
Q3 		$46.1M Buy
2,515,868
+1,394,840
+124% +$29.5M 15.3% 3
2023
Q2 		$24.2M Buy
+1,121,028
New +$30.3M 8.72% 5

Other funds holding AMLX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Stonepine Capital Management's AMLX Position: Q1 2024 in Review

Stonepine Capital Management sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2024, closing a stake of 2,500,000 shares — an estimated $36.8M sold.

Stonepine Capital Management first reported a position in AMLX in Q2 2023 and held it in 3 quarters. The position peaked at $46.1M in Q3 2023. 143 funds tracked by Wall St. Rank hold AMLX as of Q1 2024.

  • Stonepine Capital Management reported no remaining Amylyx Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Stonepine Capital Management sold 2,500,000 Amylyx Pharmaceuticals shares in Q1 2024, an estimated $36.8M.
  • Stonepine Capital Management first reported a position in Amylyx Pharmaceuticals in Q2 2023 and held it in 3 quarters.
  • Stonepine Capital Management's Amylyx Pharmaceuticals position peaked at $46.1M in Q3 2023.
  • 143 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2024.

Based on Stonepine Capital Management's 13F filing for Q1 2024, filed 15 May 2024.